Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential

Area of Science:

• Pharmaceutical Nanotechnology
• Drug Delivery Systems

Background:

• Migraine treatment often requires effective drug delivery across the blood-brain barrier.
• Sumatriptan succinate is a hydrophilic drug used for migraine management.
• Developing novel delivery systems is crucial for enhancing drug efficacy.

Purpose of the Study:

• To prepare chitosan solid lipid nanoparticles (SLN) loaded with sumatriptan succinate.
• To optimize SLN formulations for enhanced brain targeting and anti-migraine activity.
• To evaluate the potential of oral delivery for brain targeting of sumatriptan succinate.

Main Methods:

• Solvent injection method was used for chitosan SLN preparation.
• A three-factor, two-level full factorial design was employed for formulation optimization.
• Particle size, zeta potential, and entrapment efficiency were analyzed.
• In vivo studies in Wistar rats assessed brain/plasma drug concentration and anti-migraine activity.
• Nanoparticle characterization included FT-IR, DSC, TGA, XRD, and TEM.

Main Results:

• Optimized chitosan SLN exhibited particle sizes in the range of 192-301.4nm, zeta potential of 30.2-51.4mV, and entrapment efficiency of 76.3-91.1%.
• The optimized formulation demonstrated a 4.54-fold increase in the brain/blood drug ratio at 2 hours post-administration.
• In vivo and behavioral studies confirmed successful blood-brain barrier penetration and significant anti-migraine effects.

Conclusions:

• Chitosan SLN are a viable system for oral delivery of sumatriptan succinate for brain targeting.
• This approach offers an effective strategy for the therapeutic management of migraine.
• The developed nanoparticles successfully crossed the blood-brain barrier, indicating promising therapeutic potential.